Alzheimer's Drugs Market Report by Drug Class (Cholinesterase Inhibitors NMDA Receptor Antagonist Combination Drugs and Others), Drug Type (Galantamine, Donepezil, Memantine, Rivastigmine, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Region and Company Analysis 2024-2032

Alzheimer's Drugs Market Outlook

Global Alzheimer's Drugs Market was worth US$ 6.95 Billion in 2023, and the industry grew at a CAGR of 8.99% from 2024 to 2032. Thus, it can be estimated to be valued at US$ 15.08 Billion by 2032.

Alzheimer's disease (AD) reflects an ailment neurologically that advances irreversibly and displays memory loss. A declining process for cognitive abilities is there. A disease, often deadly, causes brain cells to die and degenerate. The most common cause of dementia, seen to have a severe impact on the person's capacity for function, is Alzheimer's disease. Alzheimer's disease advances in prevalence among the elderly population, thus the need. This pushes to spur the search for efficient treatments to cope with the symptoms of this disease. Research organizations and pharmaceutical corporations focus on burning pipelines to develop medications for this disease.

Consider an example- a May 2023 publication in the journal known as Translational Research & Clinical Interventions stated. They reported 187 clinical tests evaluating the treatments for Alzheimer's disease until January 2023. Hence, the progress of medicines for different target processes increases this drug development pipeline.

Refers to the word "Alzheimer's drugs"- pharmacological substances and treatments, particularly tailored to cut short the symptoms or delay the course of this Alzheimer's disease and seen in this common neurodegenerative condition primarily that affects cognitive abilities. They aim to treat all the underlying pathophysiological alterations in the brain, which are typical of Alzheimer's disease. For instance, there is the buildup of tau tangles and amyloid plaques.
In the current primary scenario, they can be divided into two groups: NMDA receptor antagonists and cholinesterase inhibitors. These inhibitors, such as galantamine, rivastigmine, and donepezil, boost neurotransmitter levels in the brain, temporarily improving cognitive function. NMDA receptor antagonists, such as memantine, regulate glutamate levels, helping ease symptoms associated with cognition and behavior.

Taking as Market Driver

The Market Growth & Awareness Increased of Alzheimer's Disease & its Treatment:

The hike seen in global awareness of Alzheimer's disease has adversely impacted the market. The symptoms came to get noticed by many more. There has been a surge in the demand for Alzheimer's medications as many more seek medical assistance. The need for Alzheimer's medication is crucial to treat Alzheimer's disease and problems related to dementia, and it is seen as increasing due to the rise in diagnoses of Alzheimer's disease.
For instance, healthcare groups have planned numerous health campaigns to enhance awareness about this disease. The Oklahoma Chapter of the Alzheimer's Association showcased. They provide a series of educational lectures to help identify indicators of Alzheimer's disease. According to data given, a MULLIN source from June 2023. They connect patients with services locally to receive guidance, support, and information about their diseases.

Seen in a rise- in government spending and programs that aim to accelerate market expansion:

Healthcare professionals are seen under increasing pressure to manage the patient pool, especially as the number of Alzheimer's disease patients sees a rise globally. Therefore, the rising need for Alzheimer's disease treatments is just expected due to some reasons. Governments are shown worldwide funding research and unstoppable launching of various actions to decrease the impact of Alzheimer's disease.
Consider, for example, that in March 2023, the Mayo Clinic received Federal funding of USD 41 million for research on Alzheimer's disease. This research program aims to find innovative therapeutic targets for Alzheimer's disease and related dementias. It works towards the next generation of precision medicine and biomarkers.

North America Alzheimer's Drugs Market:

North America reflects the largest market share and is expected to dominate the market over the projection period. The highest incidence of Alzheimer's disease in the US, recent approvals by regulatory bodies for new drugs, and sophisticated healthcare systems in that region are major influences on the growth.
For example- in February 2023, Eisai Co., Ltd. & Biogen Inc. submitted a New Drug Submission (NDS) for submitting early-stage Alzheimer's disease therapy called lecanemab to Health Canada.

Further, rising spending on healthcare support for Alzheimer's disease care is seen as a focal point in North America for market expansion. The Alzheimer's Association expects that by the year 2023, the disease will incur a cost that will hit US $345 million. By the year 2050, this expenditure pricing will reach USD 1 trillion.

Europe Alzheimer's Drugs Market:

Europe has the second-largest share globally, and the growing market is due to efforts made by various governments. These actions raise public awareness and enhance the quality of care.
For example, in November 2023, the European Medicines Agency (EMA) also approved an Alzheimer's drug called PRI-002. It is flagged to start a phase II trial. Developed by the Forschungszentrum Julich and Heinrich Heine University Düsseldorf (HHU).

Asia Pacific Alzheimer's Drugs Market:

Asia Pacific is expected to have the fastest growth projected on the global market. The highest growth is caused by some factors here, like the fast-rising prevalence of the disease in Asian countries and rising public awareness.
So, as per the proactive stance shown by the Indian Government on healthcare, the Ministry of Health & Family Welfare released data in February 2022. The data reveal funds for executing the District Mental Health Programme in approximately 704 districts.
Looking aim: Detection and treatment of all mental disorders and hence significantly avoid the chance for dementia. This is expected to contribute positively to healthcare initiatives within the country.

Alzheimer's Drugs Market Company Overview

Some of the industry leaders seen in the Global Alzheimer's Drugs Market include Abbvie Inc., AstraZeneca PLC, Biogen Inc., Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Limited.

Alzheimer's Drugs Market News

• It happened in July 2023 when a leading business called AbbVie Inc., an international bio-pharmaceutical, declared the expansion of a strategic partnership with nonprofit Scripps Research's Calibr. This partnership aims to launch the creation of several preclinical and early-stage clinical assets in the biopharmaceutical industry. Building on a current collaboration, this extension demonstrates dedication to developing disease treatments.
• Leqembi received regulatory approval in July 2023. The US FDA approved lecanemab-irmb for treating Alzheimer's disease.
• It was on May 3, 2023, that Eli Lilly & Company declared positive results for the TRAILBLAZER-ALZ 2 Phase III study. It showed that donanemab has significantly reduced cognitive and functional impairment found in people suffering from early-stage Alzheimer's disease.

Drug Class – Global Alzheimer's Drugs Market breakup in 4 viewpoints:

1.    Cholinesterase Inhibitors 
2.    NMDA Receptor Antagonist 
3.    Combination Drugs 
4.    Others

Drug Type – Global Alzheimer's Drugs Market breakup in 5 viewpoints:

1.    Galantamine
2.    Donepezil
3.    Memantine
4.    Rivastigmine
5.    Others

Distribution Channel – Global Alzheimer's Drugs Market breakup in 3 viewpoints:

1.    Hospital Pharmacies
2.    Retail Pharmacies
3.    Online Pharmacies

Country – Global Alzheimer's Drugs Market of 25 Countries Covered:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All the Key players have been covered from 4 Viewpoints:

1.    Overview
2.    Recent Development
3.    Product Portfolio
4.    Financial Insights

Company Analysis:

1.    Abbvie Inc.
2.    AstraZeneca PLC
3.    Biogen Inc.
4.    Eisai Co. Ltd.
5.    Eli Lilly and Company
6.    H. Lundbeck A/S
7.    F. Hoffmann-La Roche AG
8.    Merck & Co. Inc.
9.    Novartis AG
10.    Ono Pharmaceutical Co. Ltd.
11.    Pfizer Inc.
12.    Teva Pharmaceutical Industries Limited

Report Details: